Atypical Kinetics and Albumin Effect of Glucuronidation of 5-n-Butyl-4-{4-[2-(1H-tetrazole-5- yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6- dichlorophenyl)-3H-1,2,4-triazol-3-one, a Novel Nonpeptide Angiotensin Type 1 Receptor Antagonist, in Liver Microsomes and UDP-Glucuronosyl-transferase

Ib is a new nonpeptide AT1 receptor antagonist, which plays an active role in cardiovascular protection. Ib monoglucuronide has been identified as its main metabolite. A detailed study of Ib glucuronidation is important for predicting potential DDI. Besides, the elucidation of the “BSA effect” in Ib glucuronidation would make obtained kinetic parameters more predictive in IVIVE. “BSA effect” means that there is a significant change in in vitro kinetic parameters when generated from incubations performed in the presence of bovine serum albumin (BSA). Five UGTs (UGT1A3, UGT2B4, UGT2B7, UGT1A9 and UGT1A8) were identified that produced abundant Ib monoglucuronide, especially UGT1A3. We investigated Ib glucuronidation in liver microsomes from different species (rat, dog, human) and in five identified major human UGTs. Ib glucuronidation in liver microsomes and recombinant human UGTs all showed substrate inhibition kinetics. DLM showed the strongest affinity and activity, HLM showed the lowest affinity, and RLM showed the weakest activity. The addition of BSA did not alter the enzyme kinetics, but significantly altered enzyme kinetic parameters resulting in a reduction in Km value and an increase in CLint value. However, high concentrations of BSA could significantly attenuate this positive effect on enzyme affinity and activity, and the effect of BSA on the Vmax of Ib glucuronidation was opposite in different enzyme sources. In conclusion, this study demonstrated the substrate inhibition kinetics of Ib glucuronidation in the liver metabolism and the effect of BSA on its kinetic parameters, in order to provide more accurate in vitro data for in vivo prediction.

[1]  K. Knights,et al.  Effect of Albumin on Human Liver Microsomal and Recombinant CYP1A2 Activities: Impact on In Vitro-In Vivo Extrapolation of Drug Clearance , 2012, Drug Metabolism And Disposition.

[2]  Guangji Wang,et al.  Glucuronidation of Edaravone by Human Liver and Kidney Microsomes: Biphasic Kinetics and Identification of UGT1A9 as the Major UDP-Glucuronosyltransferase Isoform , 2012, Drug Metabolism and Disposition.

[3]  Jari Yli-Kauhaluoma,et al.  Bovine Serum Albumin Decreases Km Values of Human UDP-Glucuronosyltransferases 1A9 and 2B7 and Increases Vmax Values of UGT1A9 , 2011, Drug Metabolism and Disposition.

[4]  J. Miners,et al.  In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance , 2011, European Journal of Clinical Pharmacology.

[5]  J. Miners,et al.  In Vitro–In Vivo Extrapolation Predicts Drug–Drug Interactions Arising from Inhibition of Codeine Glucuronidation by Dextropropoxyphene, Fluconazole, Ketoconazole, and Methadone in Humans , 2010, Journal of Pharmacology and Experimental Therapeutics.

[6]  K. Knights,et al.  The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential , 2010, Drug metabolism reviews.

[7]  Yasuhiro Aoki,et al.  Quantitative Analysis of UDP-Glucuronosyltransferase (UGT) 1A and UGT2B Expression Levels in Human Livers , 2009, Drug Metabolism and Disposition.

[8]  Bill J Smith,et al.  Prediction of Human Pharmacokinetics From Preclinical Information: Comparative Accuracy of Quantitative Prediction Approaches , 2009, Journal of clinical pharmacology.

[9]  Shuji Ohno,et al.  Determination of mRNA Expression of Human UDP-Glucuronosyltransferases and Application for Localization in Various Human Tissues by Real-Time Reverse Transcriptase-Polymerase Chain Reaction , 2009, Drug Metabolism and Disposition.

[10]  Xiao-ming Wu,et al.  PKC-dependent extracellular signal-regulated kinase 1/2 pathway is involved in the inhibition of Ib on AngiotensinII-induced proliferation of vascular smooth muscle cells. , 2008, Biochemical and biophysical research communications.

[11]  Andrew Rowland,et al.  The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT) 1A9 Substrates but Not UGT1A1 and UGT1A6 Activities , 2008, Drug Metabolism and Disposition.

[12]  K. Knights,et al.  The “Albumin Effect” and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9 , 2008, Drug Metabolism and Disposition.

[13]  Xiao-ming Wu,et al.  [Ca2+]i and PKC-alpha are involved in the inhibitory effects of Ib, a novel nonpeptide AngiotensinII subtype AT1 receptor antagonist, on AngiotensinII-induced vascular contraction in vitro. , 2007, Biochemical and biophysical research communications.

[14]  Guangji Wang,et al.  Identification of the major metabolites of 5-n-butyl-4-{4-[2-(1H-tetrazole-5-yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6-dichloridephenyl)-3H-1,2,4-triazol-3-one, a new angiotensin type 1 receptor antagonist, in rat bile by HPLC-diode array detection-MS and HPLC-MS/MS. , 2007, Biomedical chromatography : BMC.

[15]  Andrew Rowland,et al.  Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation , 2007, Journal of Pharmacology and Experimental Therapeutics.

[16]  Wu Xiaoming,et al.  Effects of a new angiotensin type 1 receptor antagonist Ib on the cardiac hypertrophy induced by L-thyroxin in rats , 2006 .

[17]  K. Knights,et al.  S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. , 2005, British journal of clinical pharmacology.

[18]  Huanqiu Song,et al.  Antihypertensive Effects of a New Angiotensin Type 1 Receptor Antagonist Ib on Rats , 2005 .

[19]  K. Knights,et al.  Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. , 2004, Biochemical pharmacology.

[20]  D. Greenblatt,et al.  Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[21]  A. D. Rodrigues,et al.  Effect of albumin on phenytoin and tolbutamide metabolism in human liver microsomes: an impact more than protein binding. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[22]  T. Tracy,et al.  Atypical kinetic profiles in drug metabolism reactions. , 2002, Drug metabolism and disposition: the biological fate of chemicals.

[23]  A. D. Rodrigues,et al.  Enzyme kinetics of cytochrome P450-mediated reactions. , 2012, Current drug metabolism.

[24]  D. Greenblatt,et al.  In vitro approaches to predicting drug interactions in vivo. , 1998, Biochemical pharmacology.

[25]  J. Strong,et al.  Effect of albumin on the estimation, in vitro, of phenytoin Vmax and Km values: implications for clinical correlation. , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  J B Houston,et al.  Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. , 1994, Biochemical pharmacology.

[27]  R. Miller,et al.  Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753. , 1991, Drug metabolism and disposition: the biological fate of chemicals.